P
QTTB icon

Pfizer’s Q32 Bio QTTB Stock Holding History

Pfizer’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-101,618
Closed -$737K – 18
2026
Q1 		$737K Sell
101,618
-176,159
-63% -$837K 0.31% 15
2025
Q4 		$922K Hold
277,777
– – 0.39% 14
2025
Q3 		$550K Hold
277,777
– – 0.13% 17
2025
Q2 		$414K Hold
277,777
– – 0.07% 18
2025
Q1 		$458K Hold
277,777
– – 0.09% 18
2024
Q4 		$956K Buy
+277,777
New +$8.77M 0.04% 20

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer's QTTB Position: Q2 2026 in Review

Pfizer sold out of Q32 Bio (QTTB) in Q2 2026, closing a stake of 101,618 shares — an estimated $737K sold.

Pfizer first reported a position in QTTB in Q4 2024 and held it in 6 quarters. The position peaked at $956K in Q4 2024. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Pfizer reported no remaining Q32 Bio position as of Q2 2026 after selling out during the quarter.
  • Pfizer sold 101,618 Q32 Bio shares in Q2 2026, an estimated $737K.
  • Pfizer first reported a position in Q32 Bio in Q4 2024 and held it in 6 quarters.
  • Pfizer's Q32 Bio position peaked at $956K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.